Background and importance The use of intravenous immunoglobulins (IVIg) has increased as a result of their therapeutic usefulness in a great number of diseases. Despite this, IVIg label indications remain limited, so it is interesting to study their off-label use.
Aim and objectives To describe the use of IVIg in our hospital for 3 months and to determine if they have been used for labelled indications.
Material and methods This was a retrospective study (October–December 2018) and a descriptive analysis of the use of IVIg per patient and clinical indication. Information was collected from the hospital’s information systems and the computer records of the Farmatools software.
Results Eighty-nine patients received IVIG during the study period, with an average age of 61 years at the end of the study (3 months–86.7 years); there were 40 (45%) men and 49 (55%) women. When IVIg were used as replacement therapy, the dosage used was 200–400 mg/kg every 3–5 weeks. In the remaining indications, the dose used per treatment cycle was 1–2 g/kg divided over 2–5 days. IVIG were used for labelled indications in 80% of patients (71/89) compared with 20% for off-label indications (18/89). Among the latter, the indications were: demyelinating neuropathies (6/18), myasthenia gravis (2/18), myopathies (2/18), encephalitis/encephalomyelitis (2/18), Morvan syndrome (1/18), syndrome paraneoplastic (1/18), refractory atopic dermatitis (1/18), paraneoplastic dermatomyositis (1/18), scleroderma (1/28) and antisynthetase syndrome (1/18).
Conclusion and relevance The use of IVIG in unauthorised indications was frequent (20%), mainly in the field of neurology. This justifies the development of a protocol for the use of IVIG in this field for those indications with more scientific evidence and more common use: demyelinating neuropathies, myasthenia gravis and myopathies.
References and/or acknowledgements No conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.